ReviewJournal of translational medicine2025
Droplet-based single-cell RNA sequencing: decoding cellular heterogeneity for breakthroughs in cancer, reproduction, and beyond.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- scASprofiler: profiling single-cell RNA splicing with a deep convolutional generative network.Briefings in bioinformatics · 2026Article
- RNA Chemical Modifications in Mammalian Skeletal Muscle Development, Homeostasis, and Disease: Regulatory Mechanisms and Chemical Biology Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Single-cell long- and short-read transcriptomics sheds light on high-altitude adaptation in the porcine cerebral cortex.Translational psychiatry · 2026Article
- Review
- Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy.Frontiers in immunology · 2026Article
- Tumor heterogeneity as a driver of drug resistance and its implications for personalized therapy.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing.Frontiers in immunology · 2025Review
- Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases.Frontiers in neurologyReview
- Spatiotemporal Control of microRNA-Target Interactions.Wiley interdisciplinary reviews. RNAReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Droplet-based single-cell RNA sequencing (scRNA-seq) has redefined biological research by resolving cellular heterogeneity with an unprecedented precision. This review synthesizes the technological evolution of the 10× Genomics Chromium platform, its Gel Bead-in-Emulsion (GEM)s technology, and end-to-end workflows, while critically addressing persistent challenges, such as cell capture variability (30-75% efficiency), barcode collisions (< 5% multiplet rates), and mRNA capture limitations (10-50% efficiency). We spotlight two transformative applications: (1) cancer research, where scRNA-seq unveils rare circulating tumor cells (CTCs) and dynamic tumor microenvironments, and (2) reproductive medicine, enabling breakthroughs in primordial germ cell (PGC) epigenetics and pre-implantation diagnostics. Unlike prior reviews, we systematically evaluated innovative solutions-including UMIs, computational demultiplexing, and microfluidic cost-reduction strategies (40-60% savings)-and propose a roadmap for integrating spatial transcriptomics and multi-omics approaches. Looking ahead, we identify three frontiers poised to redefine the field: (i) single-cell epigenome-transcriptome co-profiling, (ii) AI-driven analysis of multimodal datasets, and (iii) scalable microfluidics for clinical adoption. This review is of key significance in bridging cutting-edge technology with translational impact in oncology and reproductive biology, while outlining a roadmap for the evolution of the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.